Canadian Fabry Disease Initiative (CFDI) National Registry (CFDI-NR)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00455104 |
|
Recruitment Status :
Recruiting
First Posted : April 3, 2007
Last Update Posted : March 11, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
CFDI NATIONAL REGISTRY
Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60.
Fabry Disease is estimated to affect approximately one out of every 40,000 males and up to twice as many females in Canada. We do not have the exact number of persons in Canada who have this disease. A common problem in studying rare conditions is the difficulty in identifying the majority of people suffering from such a disease. Gathering their health information in order to better understand the natural disease progression and its response to treatment is difficult.
Early ERT studies involving humans had small numbers of subjects and the studies were of short duration. The results of these clinical studies did lead to approval of the therapy in many countries around the world including Canada. To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high. As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT and other treatments to better document its true clinical outcomes in Canadian people with Fabry disease.
The Canadian Fabry Disease Initiative National Registry (CFDI-NR) is an observational, voluntary registry designed to collect outcomes data on Fabry disease from people living in Canada.
| Condition or disease | Intervention/treatment |
|---|---|
| Fabry Disease | Other: No intervention |
CFDI NATIONAL REGISTRY: Canada-Wide Patient Recruitment
There are over 600 people in Canada known to have Fabry Disease. For more details about Fabry Disease, please refer to the "Brief Summary."
The goals of this nation-wide study are as follows:
- To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada;
- To determine clinical outcomes of patients with Fabry disease including those on treatment;
- To determine if urine and plasma Gb3 and globotriasylsphingosine (LysoGb3) and their analogues can be biomarkers for Fabry disease and can predict clinical outcomes.
Data will be collected at baseline and every 12 months, as follows:
- Medical History
- Physical examination
- Neurological exam
- Electrocardiogram (ECG) - an electrical tracing of one's heart rhythm
- Echocardiogram (ultrasound of the heart)
- Holter monitor
- Magnetic Resonance Imaging (MRI) or CT Scan of the head
- Lab tests (including alpha-galactosidase levels)
- Review of current medications
- 24-hour urine collection or a random spot urine test
- Biomarker samples
To date though, evidence of the usefulness of ERT and its direct impact on the natural course of Fabry disease has been limited, while its cost continues to be very high (approximately $300,000 CDN per year per patient). As a result of these issues, there will need to be continued and long-term collection of information related to the effectiveness of ERT and other treatments to better document its true clinical outcomes in Canadian people with Fabry disease.
| Study Type : | Observational [Patient Registry] |
| Estimated Enrollment : | 600 participants |
| Observational Model: | Other |
| Time Perspective: | Other |
| Target Follow-Up Duration: | 10 Years |
| Official Title: | Canadian Fabry Disease Initiative National Registry: Outcomes of Rare Disease Therapeutics and Cardiovascular Risk Factor Modification |
| Actual Study Start Date : | January 2007 |
| Estimated Primary Completion Date : | October 2029 |
| Estimated Study Completion Date : | October 2029 |
| Group/Cohort | Intervention/treatment |
|---|---|
|
National Registry
To maintain an established national registry which will collect information related to the identification and monitoring of all persons with Fabry disease in Canada.
|
Other: No intervention
This is an observational, voluntary registry. |
- (1) To maintain an established national database for the identification and monitoring of all patients with Fabry disease in Canada. [ Time Frame: 2019 ]
- 2) To identify the clinical outcomes of patients with Fabry disease including those on various treatments. [ Time Frame: 2019 ]
- 3) To determine if urine and Gb3 and lysoGb3 and their analogues can be biomarkers for Fabry disease and can predict clinical outcomes. [ Time Frame: 2019 ]
Biospecimen Retention: Samples Without DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 5 Years to 85 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
INCLUSION CRITERIA:
- Age 5 years and older, up to & including age 85 years; and
- Able to give informed consent; and
- A clinical diagnosis of Fabry disease; and
- Compliance with all the clinic visits, interviews and assessments during the study period; and
- A Canadian citizen or a landed immigrant
EXCLUSION CRITERIA:
- Inability to give informed consent; or
- Problem complying with all the clinic visits, interviews and assessments during the study period; or
- An estimated life expectancy of less than 12 months
- Under 5 years of age
- Non-disease causing mutation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455104
| Contact: Michael L. West, MD | 902-473-4023 | mlwest@dal.ca | |
| Contact: Kaye Le Moine, RN | 902-473-5770 | kaye.lemoine@cdha.nshealth.ca |
| Canada, Alberta | |
| Alberta Children's Hospital | Recruiting |
| Calgary, Alberta, Canada, T2T 5C7 | |
| Contact: Aneal Khan, MD 403-955-7211 aneal.khan@albertahealthservices.ca | |
| Contact: Colleen McNeil 403-955-7941 colleen.mcneil@albertahealthservices.ca | |
| Principal Investigator: Aneal Khan, MD | |
| Canada, British Columbia | |
| Vancouver General Hospital Adult Metabolic Diseases Clinic | Recruiting |
| Vancouver, British Columbia, Canada, V5Z 1M9 | |
| Contact: Anna Lehman, MD 604-875-5965 anna.lehman@vch.ca | |
| Contact: Caroline Selvage, RN 604-875-5965 caroline.selvage@vch.ca | |
| Principal Investigator: Anna Lehman, MD, FRCPC | |
| Canada, Nova Scotia | |
| Queen Elizabeth II Health Sciences Centre | Recruiting |
| Halifax, Nova Scotia, Canada, B3H 1V8 | |
| Contact: Michael L West, MD 902-473-4023 mlwest@dal.ca | |
| Contact: Laurie Kay, RN 902-473-2082 laurie.kay@cdha.nshealth.ca | |
| Principal Investigator: Michael L West, MD | |
| Canada, Ontario | |
| Toronto Western Hospital | Recruiting |
| Toronto, Ontario, Canada, M5T 2S8 | |
| Contact: Mark R. Iwanochko, MD, FRCPC 416-603-5236 robertmark.iwanochko@uhn.on.ca | |
| Contact: Syed Wasim 416-586-4800 ext 4231 syed.wasim@sickkids.ca | |
| Principal Investigator: Mark R Iwanochko, MD, FRCPC | |
| Canada, Quebec | |
| University of Montreal, Department of Medicine | Recruiting |
| Montreal, Quebec, Canada | |
| Contact: Daniel Bichet, MD 514-338-2222 ext 2173 daniel.bichet@umontreal.ca | |
| Contact: Carole Fortier, RN 514-338-2222 ext 3110 c-fortier@crhsc.rtss.qc.ca | |
| Principal Investigator: Daniel Bichet, MD | |
| Principal Investigator: | Michael L West, MD | Queen Elizabeth II Health Sciences Centre (Capital District Health Authority), Halifax, Nova Scotia, Canada |
| Responsible Party: | Canadian Fabry Research Consortium |
| ClinicalTrials.gov Identifier: | NCT00455104 |
| Other Study ID Numbers: |
CFDI 001 - NR |
| First Posted: | April 3, 2007 Key Record Dates |
| Last Update Posted: | March 11, 2022 |
| Last Verified: | March 2022 |
|
Fabry Disease National Registry |
|
Fabry Disease Sphingolipidoses Lysosomal Storage Diseases, Nervous System Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases Nervous System Diseases Cerebral Small Vessel Diseases Cerebrovascular Disorders |
Vascular Diseases Cardiovascular Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Metabolism, Inborn Errors Lipidoses Lipid Metabolism, Inborn Errors Lysosomal Storage Diseases Metabolic Diseases Lipid Metabolism Disorders |